Group 1: Report Overview - The report is about a research on Jianmin Group in the traditional Chinese medicine industry, with a research date of July 1, 2025 [1][2] Group 2: Research Basic Information - The research object is Jianmin Group, belonging to the traditional Chinese medicine industry, and the reception time was on July 1, 2025. The company's reception personnel included the company's director and president Wang Jun, board secretary Zhou Jie, securities affairs representative Cao Hong, and securities affairs assistant Wang Miao [17] Group 3: Detailed Research Institutions - The research institution is Liuhe Investment, a fund management company [20] Group 4: Main Content Product Sales - In 2025, the company optimized its marketing assessment system, advancing from "net sales assessment" to "net sales + profit". It overcame factors like consumption decline and reduced pharmacy foot - traffic in Q1 and achieved growth in pharmaceutical industry sales revenue. Longmu Zhuanggu Granules saw increased sales revenue and improved sales structure, while Biantong Capsules and Jianpi Shengxue Granules maintained good momentum. Hospital - line product sales were stable, and new product sales grew [22] Emerging Business - The company's traditional Chinese medicine diagnosis and treatment and big - health business are emerging. The traditional Chinese medicine diagnosis and treatment business developed healthily, with one new clinic opened in H1 and a total of four clinics in operation in Hanyang, Hankou, Wuchang, and Optics Valley. The big - health business focused on children's healthy growth, increasing core variety cultivation and differentiated product development [23] Innovative Traditional Chinese Medicine Sales - Since 2021, the company has successively obtained approvals for three innovative drugs. In 2025, it accelerated the commercialization of new products like Xiao'er Zibei Xuanfei Syrup and Qirui Weishu Capsules, with smooth market development. Xiao'er Niuhuang Tuire Plaster was newly approved, and its listing preparations are on schedule and will participate in this year's medical insurance negotiation. The company also increased R & D investment, advanced new drug projects, and optimized its product pipeline [24][25] Future Development Plan - The company will continue to focus on the core business of traditional Chinese patent medicine manufacturing, accelerate the incubation of emerging businesses, and achieve the "1 + N" strategic goal. Specific strategic measures are detailed in the company's "2024 Annual Report" and "June 2025 Investor Relations Activity Record" [26] Advertising and Marketing - As an OTC brand pharmaceutical company, it will strengthen brand power, create "Longmu" children's medicine brand and "Jianmin" chronic disease/family - essential medicine brand. It uses multiple advertising channels such as long - form videos, short - form videos, variety shows, CCTV, and elevator media, with advertising volume similar to last year [27] Marketing System Reform - In 2024, the company carried out a comprehensive marketing system reform. In 2025, it added profit contribution assessment on the basis of net sales assessment. It optimized the organizational structure, promoted digital construction, and reduced terminal inventory. As of the end of 2024, the channel inventory of Longmu Zhuanggu Granules on the OTC line and major products on the prescription line had basically returned to a reasonable level [28] Impact of Chinese Herbal Medicine Price - The overall decline in Chinese herbal medicine prices is beneficial for the company's cost reduction and profit improvement. The company's manufacturing center uses multiple procurement models and strengthens cooperation with upstream suppliers to ensure stable raw material supply [29][30]

Group 1 - The core viewpoint of the news is that Jianmin Group (600976) has shown a slight increase in stock price and has reported mixed financial results for the first quarter of 2025, with a decrease in total revenue but an increase in net profit [1][3] - As of July 31, 2025, Jianmin Group's stock closed at 41.65 yuan, up 0.95%, with a turnover rate of 2.41% and a trading volume of 37,000 hands, amounting to a transaction value of 153 million yuan [1] - The net inflow of main funds today was 13.82 million yuan, accounting for 9.01% of the transaction value, with significant contributions from large orders [1] Group 2 - For the first quarter of 2025, Jianmin Group reported total operating revenue of 892 million yuan, a year-on-year decrease of 8.04%, while net profit attributable to shareholders was 110 million yuan, a year-on-year increase of 10.70% [1] - The company has a current ratio of 1.646, a quick ratio of 1.456, and a debt-to-asset ratio of 40.15% [1] - Jianmin Pharmaceutical Group Co., Ltd. was established in 1993 and is primarily engaged in the pharmaceutical manufacturing industry, with a registered capital of 1.533986 billion yuan [1][2] Group 3 - Jianmin Pharmaceutical Group has made investments in 30 companies and participated in 5,000 bidding projects, indicating active engagement in the market [2] - The company holds 526 trademark registrations and 241 patent registrations, showcasing its focus on intellectual property [2] - Additionally, Jianmin Group possesses 313 administrative licenses, reflecting its compliance and operational capabilities [2]

Group 1 - The company announced the completion of its board of directors' re-election and senior management appointments on July 30 [1] - Yuan Pingdong was elected as the chairman of the 11th board of directors [1] - Wang Jun was reappointed as the president, while Huang Zhijun and Pei Xuejun were appointed as vice presidents [1] - Cheng Chaoyang was appointed as the financial director, Zhou Jie as the board secretary, and Cao Hong as the securities affairs representative [1]

Group 1 - The stock price of Jianmin Group closed at 41.26 yuan on July 30, 2025, with an increase of 0.21 yuan, representing a rise of 0.51% from the previous trading day [1] - The trading volume on that day was 168 million yuan, with a turnover rate of 2.64% [1] - Jianmin Group's main business includes pharmaceutical manufacturing and pharmaceutical commerce, with both segments contributing nearly 50% to the revenue in the 2024 financial report [1] Group 2 - On the evening of July 30, Jianmin Group announced several updates, including the completion of the 11th board of directors' re-election, the election of a new chairman, and the reappointment of CFO Cheng Chaoyang [1] - The company’s first extraordinary general meeting of shareholders in 2025 approved amendments to the company’s articles of association and other proposals [1]

Core Points - The company held its first meeting of the 11th Board of Directors on July 30, 2025, in Wuhan, with all 9 directors present, meeting legal requirements [1] - Yuan Pingdong was elected as the Chairman of the 11th Board of Directors, with unanimous support from all directors [1] - Wang Jun was reappointed as the President of the company, also receiving unanimous approval [2] - Huang Zhijun and Pei Xuejun were reappointed as Vice Presidents, with full agreement from the board [2] - Cheng Chaoyang was reappointed as the Chief Financial Officer, with unanimous support [3] - Zhou Jie was reappointed as the Board Secretary, and Cao Hong as the Securities Affairs Representative, both receiving unanimous approval [3] - The board approved the revision of 13 governance-related systems, adapting to the updated company charter approved at the 2025 first extraordinary general meeting [4] - The board authorized the office to make necessary adjustments to internal regulations, including changes in terminology related to supervisory roles [4]

Meeting Overview - The shareholders' meeting of Jianmin Pharmaceutical Group Co., Ltd. was held on July 30, 2025, in Wuhan [1] - The meeting was attended by shareholders representing 41.6122% of the total shares [1] - The meeting was presided over by the vice chairman of the board, Mr. Xu Liang, and followed legal procedures as per the Company Law and Articles of Association [1] Voting Results - All non-cumulative voting proposals were approved with significant majority support, with votes in favor ranging from 91.0178% to 99.9309% across various proposals [1][2] - Specific voting results included: - Proposal 1: 58,116,051 votes in favor (91.0444%) [1] - Proposal 2: 63,775,260 votes in favor (99.9101%) [1] - Proposal 3: 63,576,660 votes in favor (99.5990%) [2] Legal Confirmation - The meeting was legally validated by lawyers Lin Ling and Chen Lin, confirming that the meeting's convening, attendance, and voting procedures complied with the Articles of Association [3]

Core Points - The company has established an Audit Committee under the Board of Directors to enhance internal control and governance structure, in accordance with relevant laws and regulations [1][2][3] - The Audit Committee is responsible for reviewing financial information, supervising internal and external audits, and evaluating internal controls [3][4][5] - The committee consists of five members, including three independent directors, with at least one being a professional accountant [2][3][4] Group 1: Audit Committee Structure - The Audit Committee is composed of five directors who are not senior management, including three independent directors [2][3] - The committee is led by a chairperson who is an independent director with accounting expertise [2][3] - The term of the Audit Committee aligns with that of the Board of Directors, and members can be re-elected [2][3] Group 2: Responsibilities and Authority - The Audit Committee is tasked with reviewing financial reports, supervising audits, and ensuring compliance with laws and regulations [3][4][5] - It must approve significant financial disclosures and the hiring or dismissal of external auditors [3][4] - The committee is also responsible for monitoring internal audit activities and ensuring effective internal controls [4][5] Group 3: Operational Procedures - The Audit Committee meets at least quarterly, with additional meetings as needed, and requires a quorum of two-thirds of its members to proceed [6][10] - Meeting notifications must be sent at least two days in advance, and minutes must be recorded and maintained for ten years [10][12] - The committee can invite external experts for professional opinions as necessary [10][12]

关于选举第十一届董事会职工代表董事的公告 特此公告。 健民药业集团股份有限公司 董事会 二〇二五年七月三十一日 证券代码：600976 证券简称：健民集团 公告编号：2025-028 健民药业集团股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据健民药业集团股份有限公司（以下简称"公司"）2025 年第一次临时股东 大会审议通过的《公司章程（2025 修订稿）》，公司董事会成员中应至少有一名职 工代表，董事会中的职工代表董事由公司职工通过职工代表大会、职工大会、职代 会联席会或者其他形式民主选举产生。 波先生为公司第十一届董事会职工代表董事，任期自会议通过之日起至第十一届董 事会任期届满之日为止。胡振波先生简历详见附件。 胡振波先生与公司持股 5%以上的股东、实际控制人、公司其他董事、高级管理 人员不存在关联关系，未持有公司股票；胡振波先生具备担任公司董事的资格和能 力，不存在《中华人民共和国公司法》《上海证券交易所股票上市规则》《上海证 券交易所上市公司自律监管指引第 1 号——规范运作》和《公司章程》 ...

Core Viewpoint - The announcement details the completion of the board of directors' re-election and the appointment of senior management personnel at Jianmin Pharmaceutical Group Co., Ltd, highlighting the new board composition and management structure [1][2][3]. Board Re-election - The 11th board of directors consists of four non-independent directors: Mr. Wang Siyang, Mr. Yuan Pingdong, Mr. Wang Jun, and Mr. Xu Liang, along with three independent directors: Mr. Guo Yunpei, Mr. Yang Zhi, and Mr. Xin Jinguo, plus employee representative director Mr. Hu Zhenbo, serving a three-year term [1][2]. - Mr. Yuan Pingdong was elected as the chairman of the 11th board of directors [2]. Specialized Committees - The specialized committees of the board were established as follows: - Strategic and Sustainable Development Committee: Members include Yuan Pingdong, Guo Yunpei, Wang Siyang, Wang Jun, and Hu Zhenbo, with Yuan Pingdong as the convener [2]. - Audit Committee: Members include Xin Jinguo, Guo Yunpei, Yang Zhi, Pei Rong, and Xu Liang, with Xin Jinguo as the convener [2]. - Nomination Committee: Members include Guo Yunpei, Yang Zhi, Xin Jinguo, Wang Siyang, and Wang Jun, with Guo Yunpei as the convener [2]. - Compensation and Assessment Committee: Members include Yang Zhi, Guo Yunpei, Xin Jinguo, Yuan Pingdong, and Wang Siyang, with Yang Zhi as the convener [2]. - Independent directors constitute more than half of the audit, nomination, and compensation committees, with Xin Jinguo being a professional accountant [2]. Senior Management Appointments - Mr. Wang Jun was reappointed as the president of the company [2]. - Mr. Huang Zhijun and Mr. Pei Xuejun were reappointed as vice presidents [2]. - Mr. Cheng Chaoyang was reappointed as the financial director [2][3]. - Mr. Zhou Jie was reappointed as the board secretary, and Ms. Cao Hong was reappointed as the securities affairs representative [3]. Cancellation of Supervisory Board - The company will no longer have a supervisory board or supervisors, as approved by the 2025 first extraordinary shareholders' meeting and in accordance with relevant laws and regulations [4].

Core Points - Jianmin Group announced the election of Mr. Hu Zhenbo as the employee representative director of the company's 11th board of directors during a joint meeting of the labor union committee on July 30, 2025 [2] Summary by Category - **Company Announcement** - Jianmin Group held a timely joint meeting of the labor union committee on July 30, 2025 [2] - Mr. Hu Zhenbo was elected as the employee representative director [2]